These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 33035922)

  • 21. Development of the first non-hydroxamate selective HDAC6 degraders.
    Keuler T; König B; Bückreiß N; Kraft FB; König P; Schäker-Hübner L; Steinebach C; Bendas G; Gütschow M; Hansen FK
    Chem Commun (Camb); 2022 Oct; 58(79):11087-11090. PubMed ID: 36098075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.
    Vögerl K; Ong N; Senger J; Herp D; Schmidtkunz K; Marek M; Müller M; Bartel K; Shaik TB; Porter NJ; Robaa D; Christianson DW; Romier C; Sippl W; Jung M; Bracher F
    J Med Chem; 2019 Feb; 62(3):1138-1166. PubMed ID: 30645113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Functional differences in epigenetic modulators-superiority of mercaptoacetamide-based histone deacetylase inhibitors relative to hydroxamates in cortical neuron neuroprotection studies.
    Kozikowski AP; Chen Y; Gaysin A; Chen B; D'Annibale MA; Suto CM; Langley BC
    J Med Chem; 2007 Jun; 50(13):3054-61. PubMed ID: 17539623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histone Deacetylase 6-Selective Inhibitors and the Influence of Capping Groups on Hydroxamate-Zinc Denticity.
    Porter NJ; Osko JD; Diedrich D; Kurz T; Hooker JM; Hansen FK; Christianson DW
    J Med Chem; 2018 Sep; 61(17):8054-8060. PubMed ID: 30118224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Posttranslational modification and beyond: interplay between histone deacetylase 6 and heat-shock protein 90.
    Liu P; Xiao J; Wang Y; Song X; Huang L; Ren Z; Kitazato K; Wang Y
    Mol Med; 2021 Sep; 27(1):110. PubMed ID: 34530730
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development and Validation of High-Content Analysis for Screening HDAC6-Selective Inhibitors.
    Nong Y; Hou Y; Pu Y; Li S; Lan Y
    SLAS Discov; 2021 Jun; 26(5):628-641. PubMed ID: 33783263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis and biological evaluation of brain penetrant benzazepine-based histone deacetylase 6 inhibitors for alleviating stroke-induced brain infarction.
    Guo Z; Zhang Z; Zhang Y; Wang G; Huang Z; Zhang Q; Li J
    Eur J Med Chem; 2021 Jun; 218():113383. PubMed ID: 33799069
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structure-activity relationship study of thiazolyl-hydroxamate derivatives as selective histone deacetylase 6 inhibitors.
    Nam G; Jung JM; Park HJ; Baek SY; Baek KS; Mok HY; Kim DE; Jung YH
    Bioorg Med Chem; 2019 Aug; 27(15):3408-3420. PubMed ID: 31235266
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel quinolone-based potent and selective HDAC6 inhibitors: Synthesis, molecular modeling studies and biological investigation.
    Relitti N; Saraswati AP; Chemi G; Brindisi M; Brogi S; Herp D; Schmidtkunz K; Saccoccia F; Ruberti G; Ulivieri C; Vanni F; Sarno F; Altucci L; Lamponi S; Jung M; Gemma S; Butini S; Campiani G
    Eur J Med Chem; 2021 Feb; 212():112998. PubMed ID: 33199154
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity.
    Zhang XH; Qin-Ma ; Wu HP; Khamis MY; Li YH; Ma LY; Liu HM
    J Med Chem; 2021 Feb; 64(3):1362-1391. PubMed ID: 33523672
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity.
    Wu H; Yang K; Zhang Z; Leisten ED; Li Z; Xie H; Liu J; Smith KA; Novakova Z; Barinka C; Tang W
    J Med Chem; 2019 Aug; 62(15):7042-7057. PubMed ID: 31271281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of cell migration and induction of apoptosis by a novel class II histone deacetylase inhibitor, MCC2344.
    Dawood M; Fleischer E; Klinger A; Bringmann G; Shan L; Efferth T
    Pharmacol Res; 2020 Oct; 160():105076. PubMed ID: 32659428
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structural determinants of affinity and selectivity in the binding of inhibitors to histone deacetylase 6.
    Osko JD; Christianson DW
    Bioorg Med Chem Lett; 2020 Apr; 30(8):127023. PubMed ID: 32067866
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fluorescence Polarization-Based Competition Assays to Evaluate Histone Deacetylase 6 Inhibitors.
    Ashraf QF; Quilates EJ; Olaoye OO; de Araujo ED; Gunning PT
    Methods Mol Biol; 2023; 2589():481-492. PubMed ID: 36255644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia.
    Gawel JM; Shouksmith AE; Raouf YS; Nawar N; Toutah K; Bukhari S; Manaswiyoungkul P; Olaoye OO; Israelian J; Radu TB; Cabral AD; Sina D; Sedighi A; de Araujo ED; Gunning PT
    Eur J Med Chem; 2020 Sep; 201():112411. PubMed ID: 32615502
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined Ligand and Fragment-based Drug Design of Selective Histone Deacetylase - 6 Inhibitors.
    Ruzic D; Petkovic M; Agbaba D; Ganesan A; Nikolic K
    Mol Inform; 2019 May; 38(5):e1800083. PubMed ID: 30632697
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of WO2017018805: 1,3,4-oxadiazole sulfamide derivatives as selective HDAC6 inhibitors.
    Liang YY; Zhang CM; Liu ZP
    Expert Opin Ther Pat; 2018 Aug; 28(8):647-651. PubMed ID: 30073889
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selective pharmacological inhibitors of HDAC6 reveal biochemical activity but functional tolerance in cancer models.
    Depetter Y; Geurs S; De Vreese R; Goethals S; Vandoorn E; Laevens A; Steenbrugge J; Meyer E; de Tullio P; Bracke M; D'hooghe M; De Wever O
    Int J Cancer; 2019 Aug; 145(3):735-747. PubMed ID: 30694564
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of specific HDAC6 inhibitor with anti-metastatic effects in pancreatic cancer cells through virtual screening and biological evaluation.
    Song H; Niu X; Quan J; Li Y; Yuan L; Wang J; Ma C; Ma E
    Bioorg Chem; 2020 Apr; 97():103679. PubMed ID: 32120077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of a potent non-hydroxamate histone deacetylase inhibitor by mechanism-based drug design.
    Suzuki T; Matsuura A; Kouketsu A; Nakagawa H; Miyata N
    Bioorg Med Chem Lett; 2005 Jan; 15(2):331-5. PubMed ID: 15603949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.